A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer�s Disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106
Read time: 1 mins
Last updated:12th Sep 2007
To evaluate the safety and tolerability of repeated subcutaneous (s.c.) injections of 150?g CAD106 in patients with mild AD over the 52 weeks of the study.
|Study start date||2007-09-12|